Back to News
Market Impact: 0.35
uniQure N.V. Reports FDA Priority Review of BLA for AMT-130 and Third Quarter 2026 Financial Results
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA accepted uniQure’s Biologics License Application for ifezuntirgene inilparvovec for review under the Accelerated Approval pathway and granted it Priority Review. This is a positive regulatory milestone, but the article excerpt does not report an approval decision or provide the Prescription Drug User Fee goal date.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
QURE0.75
More News
- uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Voters rebuff data centers in every ballot measure except one during the 2026 midterms
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says
- After the midterms, a bigger clash over data centers could be coming
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT